Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S, Sartore-Bianchi A. Mauri G, et al. Among authors: amatu a. Front Oncol. 2023 Mar 28;13:1147497. doi: 10.3389/fonc.2023.1147497. eCollection 2023. Front Oncol. 2023. PMID: 37056342 Free PMC article.
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
Strada MR, Palumbo R, Bernardo A, Riccardi A, Teragni C, Poggi G, Frascaroli M, Amatu A, Montagna B, Sottotetti F, Tagliaferri B, Bernardo G. Strada MR, et al. Among authors: amatu a. Clin Breast Cancer. 2012 Feb;12(1):30-9. doi: 10.1016/j.clbc.2011.11.001. Epub 2011 Dec 6. Clin Breast Cancer. 2012. PMID: 22154360 Clinical Trial.
Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE).
Sottani C, Leoni E, Porro B, Montagna B, Amatu A, Sottotetti F, Quaretti P, Poggi G, Minoia C. Sottani C, et al. Among authors: amatu a. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3543-8. doi: 10.1016/j.jchromb.2009.08.054. Epub 2009 Sep 19. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19783235
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.
Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, Villani L, Tagliaferri B, Sottotetti F, Rossi O, Pozzi E, Zappoli F, Riccardi A, Bernardo G. Poggi G, et al. Among authors: amatu a. Cardiovasc Intervent Radiol. 2009 Nov;32(6):1187-92. doi: 10.1007/s00270-009-9694-4. Cardiovasc Intervent Radiol. 2009. PMID: 19727937
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S. Sartore-Bianchi A, et al. Among authors: amatu a. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S1-5. doi: 10.1016/S0305-7372(10)70012-8. Cancer Treat Rev. 2010. PMID: 21129603 Review.
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Amatu A, et al. Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19. Clin Cancer Res. 2013. PMID: 23422094 Clinical Trial.
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Bardelli A, et al. Among authors: amatu a. Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2. Cancer Discov. 2013. PMID: 23729478 Free PMC article.
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. Misale S, et al. Among authors: amatu a. Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947. Sci Transl Med. 2014. PMID: 24553387 Free article.
87 results